News
ATRA
9.82
+0.61%
0.06
Weekly Report: what happened at ATRA last week (0715-0719)?
Weekly Report · 4d ago
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry
Atara Biotherapeutics, Inc. Share price has bounced 34% in the last month. The company's share price is still down 79% over the last year. The stock has a price-to-sales ratio of 1.5x and trails the rest of the industry. Atara's revenue growth has been going backwards and the company's forecast growth is lower than the wider industry.
Simply Wall St · 5d ago
Atara Biotherapeutics Receives Buy Rating Amidst Positive FDA Review and Solid Financial Outlook
TipRanks · 07/18 10:46
Atara lead asset tab-cel undergoes FDA priority review
Atara Biotherapeutics' lead asset tab-cel undergoes FDA priority review for a post-transplant condition. The U.S. Food and Drug Administration has granted priority review to Atara's lead asset. The company plans to launch the product early next year.
Seeking Alpha · 07/17 19:39
Atara Biotherapeutics Is Maintained at Sell by Goldman Sachs
Dow Jones · 07/17 16:08
Atara Biotherapeutics Price Target Cut to $11.00/Share From $12.50 by Goldman Sachs
Dow Jones · 07/17 16:08
Goldman Sachs Maintains Sell on Atara Biotherapeutics, Lowers Price Target to $11
Benzinga · 07/17 15:58
Atara Biotherapeutics Receives FDA Acceptance And Priority Review Of Biologics License Application For Tabelecleucel For Treatment Of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
Benzinga · 07/17 13:05
ATARA BIOTHERAPEUTICS- BLA ACCEPTANCE TRIGGERS $20 MLN MILESTONE PAYMENT WITH ADDITIONAL $60 MLN MILESTONE IF APPROVED BY FDA
Reuters · 07/17 13:00
ATARA BIOTHERAPEUTICS INC - $20M MILESTONE PAYMENT TRIGGERED BY BLA ACCEPTANCE
Reuters · 07/17 13:00
Weekly Report: what happened at ATRA last week (0708-0712)?
Weekly Report · 07/15 09:09
Friday Sector Leaders: General Contractors & Builders, Biotechnology Stocks
NASDAQ · 07/12 15:59
Weekly Report: what happened at ATRA last week (0701-0705)?
Weekly Report · 07/08 09:09
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. Grants 2,200 restricted stock units of Atara’s common stock to one newly hired employee. Atara is a leader in T-cell immunotherapy. The company is leveraging its novel allogeneic Epstein-Barr virus (EBV) T- cell platform to develop transformative therapies for patients with cancer and autoimmune diseases.
Barchart · 07/05 15:01
Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Virtual Cell Therapy Forum on July 9, 2024. Atara Biotherapeutics, Inc. Is a leader in T- cell immunotherapy to develop transformative therapies for patients with cancer and autoimmune diseases.
Barchart · 07/03 18:57
Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy
Atara Biotherapeutics is a biotech company developing allogeneic EBV T cells for oncology and autoimmune indications. The company has a world-first CAR-T approval in Europe and is nearing FDA approval. Despite fierce competition, ATRA is well-funded to deliver proof-of-concept clinical data. ATRA has an estimated cash runway into 2027 and is significantly undervalued. The major short-term risk is regulatory delays, which would require a cash raise.
Seeking Alpha · 07/03 17:39
Weekly Report: what happened at ATRA last week (0624-0628)?
Weekly Report · 07/01 09:09
Weekly Report: what happened at ATRA last week (0617-0621)?
Weekly Report · 06/24 09:09
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
Atara Biotherapeutics, Inc. Has been awarded the 2024 Prix Galien International Award for “Best Product for Orphan/Rare Diseases. Atara is the first company in the world to receive regulatory approval of an allogeneic Epstein-Barr virus T-cell immunotherapy. Ebvallo was granted marketing authorization in Europe in December 2022.
Barchart · 06/21 15:01
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ovid Therapeutics Inc dipped 65.7% after Takeda’s Skyline study in Dravet syndrome missed its primary endpoint. Interactive Strength Inc. Shares climbed 148% to $7.07 after dipping 19% on Friday. Mustang Bio, Inc. (NASDAQ:MBIO) shares jumped 145% after the company announced safety and efficacy data.
Benzinga · 06/17 17:21
More
Webull provides a variety of real-time ATRA stock news. You can receive the latest news about Atara Biotherape through multiple platforms. This information may help you make smarter investment decisions.
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.